KDR and cancer: In this context, the cancer cell targeted nanobody–PS conjugates are expected to efficiently distribute through tumors and allow light application 1–2 h after intravenous injection [19,20], while these VEGFR2 nanobody–PS conjugates are expected to interact and be taken up by the (mouse) tumor vasculature.